Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03422536 · ClinicalTrials.gov registry record · Phase 2
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
A Phase 2 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT03422536 is a Phase 2 study that has completed, run by University of Arizona. The registered enrollment target is 78 participants.
The verdict
NCT03422536, a Phase 2 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well ficlatuzumab with or without cetuximab works in treating patients with head and neck squamous cell carcinoma that has come back or spread to other places in the body and resistant to cetuximab treatment. Monoclonal antibodies, such as ficlatuzumab and cetuximab, may block growth signals that lets a tumor cell survive and reproduce, and helps the immune system recognize and fight head and neck squamous cell carcinoma.
Interventions
- BIOLOGICAL Cetuximab
- DRUG Ficlatuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2017-12-05 |
| Est. Completion | 2022-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03422536
The ClinicalTrials.gov registry entry for NCT03422536 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cetuximab is the first listed.
NCT03422536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03422536 about?
NCT03422536 is a clinical study titled "Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma". This randomized phase II trial studies how well ficlatuzumab with or without cetuximab works in treating patients with head and neck squamous cell carcinoma that has come back or spread to other places in the body and resistant to cetuximab treatment. Monoclonal antibodies, such as ficlatuzumab and ...
What is the current status of trial NCT03422536?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2017-12-05. Estimated completion is 2022-04-05.
What interventions are being tested in trial NCT03422536?
The interventions under investigation include: Cetuximab (BIOLOGICAL), Ficlatuzumab (DRUG).
Who is sponsoring clinical trial NCT03422536?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.